Pharmacological approaches to pulmonary fibrosis following COVID-19
S Lassan, T Tesar, J Tisonova… - Frontiers in …, 2023 - frontiersin.org
Background: In the past few years, COVID-19 became the leading cause of morbidity and
mortality worldwide. Although the World Health Organization has declared an end to COVID …
mortality worldwide. Although the World Health Organization has declared an end to COVID …
Host-based treatments for severe COVID-19
L Mondini, F Salton, L Trotta, C Bozzi… - Current issues in …, 2023 - mdpi.com
COVID-19 has been a global health problem since 2020. There are different spectrums of
manifestation of this disease, ranging from asymptomatic to extremely severe forms …
manifestation of this disease, ranging from asymptomatic to extremely severe forms …
[HTML][HTML] Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
T Karampitsakos, O Papaioannou, P Tsiri… - Clinical Microbiology …, 2023 - Elsevier
Objective Randomized controlled trials comparing tocilizumab and baricitinib in patients with
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …
[HTML][HTML] 2023 年GOLD 慢性阻塞性肺疾病诊断, 管理及预防全球策略更新要点解读
梁振宇， 王凤燕， 陈子正， 陈荣昌 - 中国全科医学, 2023 - chinagp.net
2023 年慢性阻塞性肺疾病全球倡议(GOLD) 维持了2022 年的基本框架,
但在慢性阻塞性肺疾病(以下简称慢阻肺) 定义, 评估, 初始治疗和随访期管理等方面进行了较大 …
但在慢性阻塞性肺疾病(以下简称慢阻肺) 定义, 评估, 初始治疗和随访期管理等方面进行了较大 …
Antibiotic consumption and antimicrobial resistance in the SARS-CoV-2 pandemic: A single-center experience
Introduction: Antimicrobial resistance and the rapid spread of multiresistant bacteria
represent one of the main public health problem in limited resources countries. This issue is …
represent one of the main public health problem in limited resources countries. This issue is …
Systemic Corticosteroids for Treating Respiratory Diseases: Less Is Better, but… When and How Is It Possible in Real Life?
AS Melani, S Croce, L Cassai, G Montuori, G Fabbri… - Pulmonary …, 2023 - Springer
Systemic corticosteroids (CSs), a keystone in pulmonology, are drugs with strong
antiinflammatory activity. They are cheap, easily available, and accessible, but with common …
antiinflammatory activity. They are cheap, easily available, and accessible, but with common …
Consumption of antibiotics in primary care setting before and during COVID-19 pandemic in republic of Srpska, Bosnia and Herzegovina
The pandemic of COVID-19 has brought many changes in health care systems at all levels
of health care. The increase in the number of cases of COVID-19 has led to overuse and …
of health care. The increase in the number of cases of COVID-19 has led to overuse and …
Correlation of Expression of MMP-2, ACE2, and TMPRSS2 Genes with Lymphopenia for Mild and Severity of COVID-19
B Ghezelbash, M Rostami… - Iranian Journal of …, 2023 - publish.kne-publishing.com
Some risk causes may be associated with the severity of COVID-19. The central host-
pathogen factors might affect infection are human receptor angiotensin-converting enzyme 2 …
pathogen factors might affect infection are human receptor angiotensin-converting enzyme 2 …
Treating COVID-19: targeting the host response, not the virus
DS Fedson - Life, 2023 - mdpi.com
In low-and middle-income countries (LMICs), inexpensive generic drugs like statins, ACE
inhibitors, and ARBs, especially if used in combination, might be the only practical way to …
inhibitors, and ARBs, especially if used in combination, might be the only practical way to …
Updated key points interpretation of global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 Report)
Z LIANG, F WANG, Z CHEN, R CHEN - Chinese General Practice, 2023 - chinagp.net
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive
Pulmonary Disease (2023 Report)(GOLD 2023) maintains the basic framework of GOLD …
Pulmonary Disease (2023 Report)(GOLD 2023) maintains the basic framework of GOLD …